| Maryland | 001-08895 | 33-0091377 | ||||||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, $1.00 par value | DOC | New York Stock Exchange | ||||||
| No. | Description | |||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 99.3 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document and contained in Exhibit 101). | |||||||
| Date: February 2, 2026 | ||||||||
| Healthpeak Properties, Inc. | ||||||||
| By: | /s/ Kelvin O. Moses | |||||||
| Kelvin O. Moses | ||||||||
| Chief Financial Officer | ||||||||
| Three Months Ended December 31, 2025 |
Three Months Ended December 31, 2024 |
||||||||||||||||||||||
| (in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||||||||||
| Diluted Net income (loss) applicable to common shares | $ | 113,848 | $ | 0.16 | $ | 4,400 | $ | 0.01 | |||||||||||||||
| Diluted Nareit FFO applicable to common shares | 333,105 | 0.47 | 311,396 | 0.44 | |||||||||||||||||||
| Diluted FFO as Adjusted applicable to common shares | 331,713 | 0.47 | 329,264 | 0.46 | |||||||||||||||||||
| Diluted AFFO applicable to common shares | 284,130 | 0.40 | 311,923 | 0.44 | |||||||||||||||||||
| Year Ended December 31, 2025 |
Year Ended December 31, 2024 |
||||||||||||||||||||||
| (in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||||||||||
| Diluted Net income (loss) applicable to common shares | $ | 70,513 | $ | 0.10 | $ | 242,491 | $ | 0.36 | |||||||||||||||
| Diluted Nareit FFO applicable to common shares | 1,287,192 | 1.81 | 1,108,941 | 1.61 | |||||||||||||||||||
| Diluted FFO as Adjusted applicable to common shares | 1,310,448 | 1.84 | 1,247,929 | 1.81 | |||||||||||||||||||
| Diluted AFFO applicable to common shares | 1,201,778 | 1.69 | 1,156,876 | 1.68 | |||||||||||||||||||
| Year-Over-Year Total Merger-Combined SS Cash (Adjusted) NOI Growth | |||||||||||||||||
| Three Month | Full Year | ||||||||||||||||
| SS Growth % | % of SS | SS Growth % | % of SS | ||||||||||||||
| Outpatient Medical | 4.1 | % | 54.1 | % | 3.9 | % | 54.8 | % | |||||||||
| Lab | (0.3 | %) | 33.9 | % | 1.5 | % | 34.1 | % | |||||||||
| Life Plan | 16.7 | % | 12.0 | % | 12.6 | % | 11.1 | % | |||||||||
| Total Merger-Combined SS Cash (Adjusted) NOI | 3.9 | % | 100.0 | % | 4.0 | % | 100.0 | % | |||||||||
| Record Date | Payment Date | Amount | ||||||
| January 16, 2026 | January 30, 2026 | $0.10167 per common share | ||||||
| February 13, 2026 | February 27, 2026 | $0.10167 per common share | ||||||
| March 17, 2026 | March 31, 2026 | $0.10167 per common share | ||||||
| December 31, 2025 |
December 31, 2024 |
||||||||||
| Assets | |||||||||||
| Real estate: | |||||||||||
| Buildings and improvements | $ | 16,593,535 | $ | 16,115,283 | |||||||
| Development costs and construction in progress | 1,010,657 | 880,393 | |||||||||
| Land and improvements | 3,007,346 | 2,918,758 | |||||||||
| Accumulated depreciation | (4,512,443) | (4,083,030) | |||||||||
| Net real estate | 16,099,095 | 15,831,404 | |||||||||
| Loans receivable, net of reserves of $11,345 and $10,499 | 606,020 | 655,917 | |||||||||
| Investments in unconsolidated joint ventures | 802,601 | 936,814 | |||||||||
| Accounts receivable, net of allowance of $2,018 and $2,243 | 78,327 | 76,810 | |||||||||
| Cash and cash equivalents | 467,457 | 119,818 | |||||||||
| Restricted cash | 70,245 | 64,487 | |||||||||
| Intangible assets | 654,516 | 817,254 | |||||||||
| Assets held for sale | 80,621 | 7,840 | |||||||||
| Right-of-use asset | 412,198 | 424,173 | |||||||||
| Deferred tax assets | 111,248 | 115,258 | |||||||||
| Goodwill | 68,529 | 68,529 | |||||||||
| Other assets | 885,161 | 819,951 | |||||||||
| Total assets | $ | 20,336,018 | $ | 19,938,255 | |||||||
| Liabilities and Equity | |||||||||||
| Bank line of credit and commercial paper | $ | 1,078,850 | $ | 150,000 | |||||||
| Term loans | 1,647,113 | 1,646,043 | |||||||||
| Senior unsecured notes | 6,772,722 | 6,563,256 | |||||||||
| Mortgage debt | 349,209 | 356,750 | |||||||||
| Intangible liabilities | 173,697 | 191,884 | |||||||||
| Liabilities related to assets held for sale | 11,900 | — | |||||||||
| Lease liability | 296,260 | 307,220 | |||||||||
| Accounts payable, accrued liabilities, and other liabilities | 718,509 | 725,342 | |||||||||
| Deferred revenue | 985,307 | 940,136 | |||||||||
| Total liabilities | 12,033,567 | 10,880,631 | |||||||||
| Commitments and contingencies | |||||||||||
| Redeemable noncontrolling interests | 159,581 | 2,610 | |||||||||
| Common stock, $1.00 par value: 1,500,000,000 shares authorized; 695,036,731 and 699,485,139 shares issued and outstanding | 695,037 | 699,485 | |||||||||
| Additional paid-in capital | 12,767,914 | 12,847,252 | |||||||||
| Cumulative dividends in excess of earnings | (5,952,920) | (5,174,279) | |||||||||
| Accumulated other comprehensive income (loss) | (9,937) | 28,818 | |||||||||
| Total stockholders’ equity | 7,500,094 | 8,401,276 | |||||||||
| Joint venture partners | 295,455 | 315,821 | |||||||||
| Non-managing member unitholders | 347,321 | 337,917 | |||||||||
| Total noncontrolling interests | 642,776 | 653,738 | |||||||||
| Total equity | 8,142,870 | 9,055,014 | |||||||||
| Total liabilities and equity | $ | 20,336,018 | $ | 19,938,255 | |||||||
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Rental and related revenues | $ | 549,029 | $ | 535,131 | $ | 2,156,743 | $ | 2,087,196 | |||||||||||||||
| Resident fees and services | 155,749 | 145,963 | 603,989 | 568,475 | |||||||||||||||||||
| Interest income and other | 14,624 | 16,894 | 61,780 | 44,778 | |||||||||||||||||||
| Total revenues | 719,402 | 697,988 | 2,822,512 | 2,700,449 | |||||||||||||||||||
| Costs and expenses: | |||||||||||||||||||||||
| Operating | 287,853 | 277,026 | 1,129,099 | 1,074,861 | |||||||||||||||||||
| Depreciation and amortization | 262,086 | 274,469 | 1,058,865 | 1,057,205 | |||||||||||||||||||
| Interest expense | 80,638 | 70,508 | 305,178 | 280,430 | |||||||||||||||||||
| General and administrative | 23,627 | 23,929 | 90,416 | 97,162 | |||||||||||||||||||
| Transaction and merger-related costs | 7,351 | 10,572 | 25,520 | 132,685 | |||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | (776) | 11,632 | (893) | 22,978 | |||||||||||||||||||
| Total costs and expenses | 660,779 | 668,136 | 2,608,185 | 2,665,321 | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Gain (loss) on sales of real estate, net | 56,352 | (8,929) | 69,488 | 178,695 | |||||||||||||||||||
| Other income (expense), net | 10,137 | (24,157) | 479 | 59,345 | |||||||||||||||||||
| Total other income (expense), net | 66,489 | (33,086) | 69,967 | 238,040 | |||||||||||||||||||
| Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 125,112 | (3,234) | 284,294 | 273,168 | |||||||||||||||||||
| Income tax benefit (expense) | (6,027) | 14,014 | (9,283) | (4,350) | |||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | 2,707 | (108) | (173,984) | (1,515) | |||||||||||||||||||
| Net income (loss) | 121,792 | 10,672 | 101,027 | 267,303 | |||||||||||||||||||
| Noncontrolling interests’ share in earnings | (7,824) | (6,125) | (29,680) | (24,161) | |||||||||||||||||||
| Net income (loss) attributable to Healthpeak Properties, Inc. | 113,968 | 4,547 | 71,347 | 243,142 | |||||||||||||||||||
| Participating securities’ share in earnings | (120) | (147) | (834) | (758) | |||||||||||||||||||
| Net income (loss) applicable to common shares | $ | 113,848 | $ | 4,400 | $ | 70,513 | $ | 242,384 | |||||||||||||||
| Earnings (loss) per common share: | |||||||||||||||||||||||
| Basic | $ | 0.16 | $ | 0.01 | $ | 0.10 | $ | 0.36 | |||||||||||||||
| Diluted | $ | 0.16 | $ | 0.01 | $ | 0.10 | $ | 0.36 | |||||||||||||||
| Weighted average shares outstanding: | |||||||||||||||||||||||
| Basic | 694,976 | 699,457 | 696,026 | 675,680 | |||||||||||||||||||
| Diluted | 694,985 | 699,596 | 696,044 | 676,233 | |||||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||
| Net income (loss) applicable to common shares | $ | 113,848 | $ | 4,400 | $ | 70,513 | $ | 242,384 | ||||||||||||||||||
| Real estate related depreciation and amortization | 262,086 | 274,469 | 1,058,865 | 1,057,205 | ||||||||||||||||||||||
| Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 12,806 | 12,441 | 50,110 | 44,961 | ||||||||||||||||||||||
| Noncontrolling interests’ share of real estate related depreciation and amortization | (3,824) | (4,622) | (16,511) | (18,328) | ||||||||||||||||||||||
| Loss (gain) on sales of depreciable real estate, net | (56,352) | 8,929 | (69,488) | (178,695) | ||||||||||||||||||||||
| Loss (gain) upon change of control, net | — | — | — | (77,548) | ||||||||||||||||||||||
| Taxes associated with real estate dispositions | — | (1,879) | (335) | 9,633 | ||||||||||||||||||||||
Impairments (recoveries) of real estate, net(1) |
— | 13,118 | 175,827 | 13,118 | ||||||||||||||||||||||
| Nareit FFO applicable to common shares | 328,564 | 306,856 | 1,268,981 | 1,092,730 | ||||||||||||||||||||||
| Distributions on dilutive convertible units and other | 4,541 | 4,540 | 18,211 | 16,211 | ||||||||||||||||||||||
| Diluted Nareit FFO applicable to common shares | $ | 333,105 | $ | 311,396 | $ | 1,287,192 | $ | 1,108,941 | ||||||||||||||||||
| Diluted Nareit FFO per common share | $ | 0.47 | $ | 0.44 | $ | 1.81 | $ | 1.61 | ||||||||||||||||||
| Weighted average shares outstanding - Diluted Nareit FFO | 709,412 | 714,648 | 710,509 | 689,638 | ||||||||||||||||||||||
| Impact of adjustments to Nareit FFO: | ||||||||||||||||||||||||||
Transaction, merger, and restructuring-related costs(2) |
$ | 7,351 | $ | 6,181 | $ | 25,520 | $ | 115,105 | ||||||||||||||||||
Other impairments (recoveries) and other losses (gains), net(3) |
(776) | (2,360) | (651) | 9,381 | ||||||||||||||||||||||
| Casualty-related charges (recoveries), net | (7,968) | 25,260 | (1,594) | 25,848 | ||||||||||||||||||||||
| Recognition (reversal) of valuation allowance on deferred tax assets | — | (11,196) | — | (11,196) | ||||||||||||||||||||||
| Total adjustments | (1,393) | 17,885 | 23,275 | 139,138 | ||||||||||||||||||||||
| FFO as Adjusted applicable to common shares | 327,171 | 324,741 | 1,292,256 | 1,231,868 | ||||||||||||||||||||||
| Distributions on dilutive convertible units and other | 4,542 | 4,523 | 18,192 | 16,061 | ||||||||||||||||||||||
| Diluted FFO as Adjusted applicable to common shares | $ | 331,713 | $ | 329,264 | $ | 1,310,448 | $ | 1,247,929 | ||||||||||||||||||
| Diluted FFO as Adjusted per common share | $ | 0.47 | $ | 0.46 | $ | 1.84 | $ | 1.81 | ||||||||||||||||||
| Weighted average shares outstanding - Diluted FFO as Adjusted | 709,412 | 714,648 | 710,509 | 689,638 | ||||||||||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| FFO as Adjusted applicable to common shares | $ | 327,171 | $ | 324,741 | $ | 1,292,256 | $ | 1,231,868 | |||||||||||||||
| Stock-based compensation amortization expense | 4,000 | 3,608 | 14,410 | 15,543 | |||||||||||||||||||
| Amortization of deferred financing costs and debt discounts (premiums) | 8,199 | 9,727 | 31,907 | 28,974 | |||||||||||||||||||
| Straight-line rents | (8,355) | (8,385) | (39,190) | (41,276) | |||||||||||||||||||
| AFFO capital expenditures | (57,825) | (39,040) | (133,951) | (115,784) | |||||||||||||||||||
| Life plan community entrance fees | 17,355 | 23,148 | 53,805 | 53,697 | |||||||||||||||||||
| Deferred income taxes | 2,739 | 3,846 | 7,728 | 6,176 | |||||||||||||||||||
| Amortization of above (below) market lease intangibles, net | (8,345) | (7,430) | (36,747) | (30,755) | |||||||||||||||||||
| Other AFFO adjustments | (5,349) | (2,832) | (6,650) | (7,778) | |||||||||||||||||||
| AFFO applicable to common shares | 279,590 | 307,383 | 1,183,568 | 1,140,665 | |||||||||||||||||||
| Distributions on dilutive convertible units and other | 4,540 | 4,540 | 18,210 | 16,211 | |||||||||||||||||||
| Diluted AFFO applicable to common shares | $ | 284,130 | $ | 311,923 | $ | 1,201,778 | $ | 1,156,876 | |||||||||||||||
| Diluted AFFO per common share | $ | 0.40 | $ | 0.44 | $ | 1.69 | $ | 1.68 | |||||||||||||||
| Weighted average shares outstanding - Diluted AFFO | 709,412 | 714,648 | 710,509 | 689,638 | |||||||||||||||||||
| Definitions | ||
![]() |
2 |
||||
| Definitions | ||
![]() |
3 |
||||
| Definitions | ||
![]() |
4 |
||||
| Definitions | ||
![]() |
5 |
||||
| Definitions | ||
![]() |
6 |
||||
| Reconciliations | ||
| Funds From Operations | ||
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Net income (loss) applicable to common shares | $ | 113,848 | $ | 4,400 | $ | 70,513 | $ | 242,384 | |||||||||||||||
| Real estate related depreciation and amortization | 262,086 | 274,469 | 1,058,865 | 1,057,205 | |||||||||||||||||||
| Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 12,806 | 12,441 | 50,110 | 44,961 | |||||||||||||||||||
| Noncontrolling interests’ share of real estate related depreciation and amortization | (3,824) | (4,622) | (16,511) | (18,328) | |||||||||||||||||||
| Loss (gain) on sales of depreciable real estate, net | (56,352) | 8,929 | (69,488) | (178,695) | |||||||||||||||||||
| Loss (gain) upon change of control, net | — | — | — | (77,548) | |||||||||||||||||||
| Taxes associated with real estate dispositions | — | (1,879) | (335) | 9,633 | |||||||||||||||||||
Impairments (recoveries) of real estate, net(1) |
— | 13,118 | 175,827 | 13,118 | |||||||||||||||||||
| Nareit FFO applicable to common shares | 328,564 | 306,856 | 1,268,981 | 1,092,730 | |||||||||||||||||||
| Distributions on dilutive convertible units and other | 4,541 | 4,540 | 18,211 | 16,211 | |||||||||||||||||||
| Diluted Nareit FFO applicable to common shares | $ | 333,105 | $ | 311,396 | $ | 1,287,192 | $ | 1,108,941 | |||||||||||||||
| Weighted average shares outstanding - Diluted Nareit FFO | 709,412 | 714,648 | 710,509 | 689,638 | |||||||||||||||||||
| Impact of adjustments to Nareit FFO: | |||||||||||||||||||||||
Transaction, merger, and restructuring-related costs(2) |
$ | 7,351 | $ | 6,181 | $ | 25,520 | $ | 115,105 | |||||||||||||||
Other impairments (recoveries) and other losses (gains), net(3) |
(776) | (2,360) | (651) | 9,381 | |||||||||||||||||||
| Casualty-related charges (recoveries), net | (7,968) | 25,260 | (1,594) | 25,848 | |||||||||||||||||||
| Recognition (reversal) of valuation allowance on deferred tax assets | — | (11,196) | — | (11,196) | |||||||||||||||||||
| Total adjustments | $ | (1,393) | $ | 17,885 | $ | 23,275 | $ | 139,138 | |||||||||||||||
| FFO as Adjusted applicable to common shares | $ | 327,171 | $ | 324,741 | $ | 1,292,256 | $ | 1,231,868 | |||||||||||||||
| Distributions on dilutive convertible units and other | 4,542 | 4,523 | 18,192 | 16,061 | |||||||||||||||||||
| Diluted FFO as Adjusted applicable to common shares | $ | 331,713 | $ | 329,264 | $ | 1,310,448 | $ | 1,247,929 | |||||||||||||||
| Weighted average shares outstanding - Diluted FFO as Adjusted | 709,412 | 714,648 | 710,509 | 689,638 | |||||||||||||||||||
| FFO as Adjusted applicable to common shares | $ | 327,171 | $ | 324,741 | $ | 1,292,256 | $ | 1,231,868 | |||||||||||||||
| Stock-based compensation amortization expense | 4,000 | 3,608 | 14,410 | 15,543 | |||||||||||||||||||
| Amortization of deferred financing costs and debt discounts (premiums) | 8,199 | 9,727 | 31,907 | 28,974 | |||||||||||||||||||
| Straight-line rents | (8,355) | (8,385) | (39,190) | (41,276) | |||||||||||||||||||
| AFFO capital expenditures | (57,825) | (39,040) | (133,951) | (115,784) | |||||||||||||||||||
| Life plan community entrance fees | 17,355 | 23,148 | 53,805 | 53,697 | |||||||||||||||||||
| Deferred income taxes | 2,739 | 3,846 | 7,728 | 6,176 | |||||||||||||||||||
| Amortization of above (below) market lease intangibles, net | (8,345) | (7,430) | (36,747) | (30,755) | |||||||||||||||||||
| Other AFFO adjustments | (5,349) | (2,832) | (6,650) | (7,778) | |||||||||||||||||||
| AFFO applicable to common shares | 279,590 | 307,383 | 1,183,568 | 1,140,665 | |||||||||||||||||||
| Distributions on dilutive convertible units and other | 4,540 | 4,540 | 18,210 | 16,211 | |||||||||||||||||||
| Diluted AFFO applicable to common shares | $ | 284,130 | $ | 311,923 | $ | 1,201,778 | $ | 1,156,876 | |||||||||||||||
| Weighted average shares outstanding - Diluted AFFO | 709,412 | 714,648 | 710,509 | 689,638 | |||||||||||||||||||
![]() |
7 |
||||
| Reconciliations | ||
| Funds From Operations | ||||||||||||||
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Diluted earnings per common share | $ | 0.16 | $ | 0.01 | $ | 0.10 | $ | 0.36 | |||||||||||||||
| Depreciation and amortization | 0.39 | 0.40 | 1.56 | 1.58 | |||||||||||||||||||
| Loss (gain) on sales of depreciable real estate, net | (0.08) | 0.01 | (0.10) | (0.26) | |||||||||||||||||||
| Loss (gain) upon change of control, net | — | — | — | (0.11) | |||||||||||||||||||
| Taxes associated with real estate dispositions | — | 0.00 | 0.00 | 0.02 | |||||||||||||||||||
Impairments (recoveries) of real estate, net(1) |
— | 0.02 | 0.25 | 0.02 | |||||||||||||||||||
| Diluted Nareit FFO per common share | $ | 0.47 | $ | 0.44 | $ | 1.81 | $ | 1.61 | |||||||||||||||
Transaction, merger, and restructuring-related costs(2) |
0.01 | 0.01 | 0.03 | 0.17 | |||||||||||||||||||
Other impairments (recoveries) and other losses (gains), net(3) |
0.00 | 0.00 | 0.00 | 0.01 | |||||||||||||||||||
| Casualty-related charges (recoveries), net | (0.01) | 0.04 | 0.00 | 0.04 | |||||||||||||||||||
| Recognition (reversal) of valuation allowance on deferred tax assets | — | (0.03) | — | (0.02) | |||||||||||||||||||
| Diluted FFO as Adjusted per common share | $ | 0.47 | $ | 0.46 | $ | 1.84 | $ | 1.81 | |||||||||||||||
| Stock-based compensation amortization expense | 0.01 | 0.01 | 0.02 | 0.02 | |||||||||||||||||||
| Amortization of deferred financing costs and debt discounts (premiums) | 0.01 | 0.01 | 0.05 | 0.04 | |||||||||||||||||||
| Straight-line rents | (0.01) | (0.01) | (0.06) | (0.06) | |||||||||||||||||||
| AFFO capital expenditures | (0.08) | (0.06) | (0.19) | (0.16) | |||||||||||||||||||
| Life plan community entrance fees | 0.02 | 0.04 | 0.08 | 0.08 | |||||||||||||||||||
| Deferred income taxes | 0.00 | 0.01 | 0.01 | 0.01 | |||||||||||||||||||
| Amortization of above (below) market lease intangibles, net | (0.01) | (0.02) | (0.05) | (0.05) | |||||||||||||||||||
| Other AFFO adjustments | (0.01) | 0.00 | (0.01) | (0.01) | |||||||||||||||||||
| Diluted AFFO per common share | $ | 0.40 | $ | 0.44 | $ | 1.69 | $ | 1.68 | |||||||||||||||
![]() |
8 |
||||
| Reconciliations | ||
2026 Guidance(1) | ||||||||||||||
| 2026 Guidance Ranges | |||||||||||
| Low | High | ||||||||||
| Diluted earnings per common share | $ | 0.34 | $ | 0.38 | |||||||
| Real estate related depreciation and amortization | 1.31 | 1.31 | |||||||||
| Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 0.07 | 0.07 | |||||||||
| Noncontrolling interests' share of real estate related depreciation and amortization | (0.02) | (0.02) | |||||||||
| Diluted Nareit FFO per common share | $ | 1.70 | $ | 1.74 | |||||||
| Diluted FFO as Adjusted per common share | $ | 1.70 | $ | 1.74 | |||||||
![]() |
9 |
||||
| Reconciliations | ||
2026 Guidance(1) | ||||||||||||||
| Total Portfolio | |||||
| Net Income | $ | 269 | |||
| Real estate related depreciation and amortization | 919 | ||||
| Other income, costs, and expense adjustments for Adjusted NOI | 313 | ||||
| Adjusted NOI | $ | 1,501 | |||
| Merger-Combined non-SS Adjusted NOI | (148) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI(2) |
$ | 1,353 | |||
| Total Portfolio | |||||
| Net Income | $ | 296 | |||
| Real estate related depreciation and amortization | 919 | ||||
| Other income, costs, and expense adjustments for Adjusted NOI | 313 | ||||
| Adjusted NOI | $ | 1,528 | |||
| Merger-Combined non-SS Adjusted NOI | (148) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI(2) |
$ | 1,380 | |||
| Total Portfolio | |||||
| Net Income | $ | 101 | |||
| Real estate related depreciation and amortization | 1,059 | ||||
| Loss (gain) on sales of depreciable real estate, net | (69) | ||||
| Other impairments (recoveries) and other losses (gains), net | (1) | ||||
| Other income, costs, and expense adjustments for Adjusted NOI | 461 | ||||
| Adjusted NOI | $ | 1,551 | |||
| Merger-Combined non-SS Adjusted NOI | (184) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI(2) |
$ | 1,367 | |||
| Low | (1.00) | % | |||
| High | 1.00 | % | |||
![]() |
10 |
||||
| Reconciliations | ||
| Enterprise Gross Assets | ||||||||||||||
| December 31, 2025 | |||||
Consolidated total assets(1) |
$ | 20,336,018 | |||
| Investments in and advances to unconsolidated joint ventures | (802,601) | ||||
| Accumulated depreciation and amortization of real estate | 4,512,443 | ||||
| Accumulated amortization of real estate intangibles | 722,522 | ||||
| Accumulated depreciation and amortization of real estate assets held for sale | 85,894 | ||||
| Consolidated Gross Assets | $ | 24,854,276 | |||
| Healthpeak's share of unconsolidated joint venture gross assets | 1,295,692 | ||||
| Enterprise Gross Assets | $ | 26,149,968 | |||
| Portfolio Investment | ||
| December 31, 2025 | |||||||||||||||||||||||||||||
| Outpatient Medical |
Lab | Life Plan | Other | Total | |||||||||||||||||||||||||
| Net real estate | $ | 6,807,262 | $ | 7,648,090 | $ | 1,643,743 | $ | — | $ | 16,099,095 | |||||||||||||||||||
| Real estate assets held for sale, net | 13,211 | 59,301 | — | — | 72,512 | ||||||||||||||||||||||||
| Intangible assets, net | 459,777 | 168,069 | 26,670 | — | 654,516 | ||||||||||||||||||||||||
| Accumulated depreciation and amortization of real estate | 2,250,911 | 1,753,154 | 508,378 | — | 4,512,443 | ||||||||||||||||||||||||
| Accumulated amortization of real estate intangibles assets | 408,465 | 59,371 | 254,686 | — | 722,522 | ||||||||||||||||||||||||
| Accumulated depreciation and amortization of real estate assets held for sale | 33,975 | 51,919 | — | — | 85,894 | ||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture gross real estate assets | 259,434 | 596,156 | — | 489,762 | 1,345,352 | ||||||||||||||||||||||||
| Fully depreciated and amortized real estate and intangibles assets | 964,842 | 721,044 | 81,684 | — | 1,767,570 | ||||||||||||||||||||||||
| Leasing commissions and other | 190,208 | 131,497 | — | — | 321,705 | ||||||||||||||||||||||||
| Debt investments | — | — | — | 685,010 | 685,010 | ||||||||||||||||||||||||
| Real estate intangible liabilities, gross | (236,168) | (221,968) | — | — | (458,136) | ||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture real estate and related intangibles | (445,300) | — | — | — | (445,300) | ||||||||||||||||||||||||
| Portfolio Investment | $ | 10,706,617 | $ | 10,966,633 | $ | 2,515,161 | $ | 1,174,772 | $ | 25,363,183 | |||||||||||||||||||
![]() |
11 |
||||
| Reconciliations | ||
| Revenues | ||
| Three Months Ended | ||||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Outpatient Medical | $ | 317,298 | $ | 320,548 | $ | 320,482 | $ | 326,561 | $ | 329,086 | ||||||||||||||||||||||
| Lab | 217,833 | 217,593 | 209,205 | 213,325 | 219,943 | |||||||||||||||||||||||||||
| Life Plan | 145,963 | 148,927 | 148,855 | 150,458 | 155,749 | |||||||||||||||||||||||||||
| Other | 15,199 | 14,332 | 14,288 | 14,092 | 13,453 | |||||||||||||||||||||||||||
| Corporate Non-segment | 1,695 | 1,489 | 1,518 | 1,437 | 1,171 | |||||||||||||||||||||||||||
| Total revenues | $ | 697,988 | $ | 702,889 | $ | 694,348 | $ | 705,873 | $ | 719,402 | ||||||||||||||||||||||
| Outpatient Medical | — | — | — | — | — | |||||||||||||||||||||||||||
| Lab | — | — | — | — | — | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | (15,199) | (14,332) | (14,288) | (14,092) | (13,453) | |||||||||||||||||||||||||||
| Corporate Non-segment | (1,695) | (1,489) | (1,518) | (1,437) | (1,171) | |||||||||||||||||||||||||||
| Less: Interest income and other | $ | (16,894) | $ | (15,821) | $ | (15,806) | $ | (15,529) | $ | (14,624) | ||||||||||||||||||||||
| Outpatient Medical | 7,334 | 7,259 | 7,183 | 7,327 | 7,597 | |||||||||||||||||||||||||||
| Lab | 5,329 | 2,800 | 7,358 | 6,834 | 8,311 | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | 21,845 | 22,459 | 22,460 | 22,494 | 22,025 | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture real estate revenues | $ | 34,508 | $ | 32,518 | $ | 37,001 | $ | 36,655 | $ | 37,933 | ||||||||||||||||||||||
| Outpatient Medical | (9,692) | (9,973) | (10,020) | (10,334) | (10,755) | |||||||||||||||||||||||||||
| Lab | — | — | — | — | (137) | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | — | — | — | — | — | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture real estate revenues | $ | (9,692) | $ | (9,973) | $ | (10,020) | $ | (10,334) | $ | (10,892) | ||||||||||||||||||||||
| Outpatient Medical | (13,181) | (13,426) | (12,470) | (12,021) | (12,260) | |||||||||||||||||||||||||||
| Lab | (12,550) | (14,557) | (12,202) | (15,312) | (21,386) | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | (94) | (7) | 67 | (15) | (38) | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Non-cash adjustments to real estate revenues | $ | (25,825) | $ | (27,990) | $ | (24,605) | $ | (27,348) | $ | (33,684) | ||||||||||||||||||||||
| Outpatient Medical | 301,759 | 304,408 | 305,175 | 311,532 | 313,667 | |||||||||||||||||||||||||||
| Lab | 210,612 | 205,836 | 204,362 | 204,847 | 206,730 | |||||||||||||||||||||||||||
| Life Plan | 145,963 | 148,927 | 148,855 | 150,458 | 155,749 | |||||||||||||||||||||||||||
| Other | 21,751 | 22,452 | 22,527 | 22,479 | 21,987 | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Portfolio Cash Real Estate Revenues | $ | 680,085 | $ | 681,623 | $ | 680,919 | $ | 689,316 | $ | 698,133 | ||||||||||||||||||||||
![]() |
12 |
||||
| Reconciliations | ||
| Revenues | ||
| Three Months Ended | ||||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Outpatient Medical | $ | (20,584) | $ | (20,322) | $ | (20,237) | $ | (20,674) | $ | (20,850) | ||||||||||||||||||||||
| Lab | (41,731) | (36,740) | (36,962) | (37,610) | (36,394) | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | (21,751) | (22,452) | (22,527) | (22,479) | (21,987) | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Merger-Combined non-SS Cash Real Estate Revenues | $ | (84,066) | $ | (79,514) | $ | (79,726) | $ | (80,763) | $ | (79,231) | ||||||||||||||||||||||
| Outpatient Medical | 281,175 | 284,086 | 284,938 | 290,858 | 292,817 | |||||||||||||||||||||||||||
| Lab | 168,881 | 169,096 | 167,400 | 167,237 | 170,336 | |||||||||||||||||||||||||||
| Life Plan | 145,963 | 148,927 | 148,855 | 150,458 | 155,749 | |||||||||||||||||||||||||||
| Other | — | — | — | — | — | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Merger-Combined SS Cash Real Estate Revenues | $ | 596,019 | $ | 602,109 | $ | 601,193 | $ | 608,553 | $ | 618,902 | ||||||||||||||||||||||
![]() |
13 |
||||
| Reconciliations | ||
| Operating Expenses | ||
| Three Months Ended | ||||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Outpatient Medical | $ | 106,539 | $ | 105,226 | $ | 105,331 | $ | 113,660 | $ | 111,834 | ||||||||||||||||||||||
| Lab | 62,049 | 57,658 | 59,401 | 64,352 | 63,783 | |||||||||||||||||||||||||||
| Life Plan | 108,438 | 110,259 | 111,449 | 113,910 | 112,236 | |||||||||||||||||||||||||||
| Other | — | — | — | — | — | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Operating expenses | $ | 277,026 | $ | 273,143 | $ | 276,181 | $ | 291,922 | $ | 287,853 | ||||||||||||||||||||||
| Outpatient Medical | 2,655 | 2,994 | 2,695 | 2,887 | 2,796 | |||||||||||||||||||||||||||
| Lab | 1,703 | 1,666 | 1,898 | 2,229 | 2,486 | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | 16,224 | 16,324 | 16,440 | 16,855 | 16,751 | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture operating expenses | $ | 20,582 | $ | 20,984 | $ | 21,033 | $ | 21,971 | $ | 22,033 | ||||||||||||||||||||||
| Outpatient Medical | (2,692) | (2,778) | (2,801) | (3,765) | (3,921) | |||||||||||||||||||||||||||
| Lab | — | — | — | — | (99) | |||||||||||||||||||||||||||
| Life Plan | — | — | — | — | — | |||||||||||||||||||||||||||
| Other | — | — | — | — | — | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture operating expenses | $ | (2,692) | $ | (2,778) | $ | (2,801) | $ | (3,765) | $ | (4,020) | ||||||||||||||||||||||
| Outpatient Medical | (1,791) | (1,344) | (1,657) | (1,663) | (1,470) | |||||||||||||||||||||||||||
| Lab | 275 | 279 | 286 | 208 | 260 | |||||||||||||||||||||||||||
| Life Plan | 1,479 | — | 843 | — | 1,647 | |||||||||||||||||||||||||||
| Other | (88) | (11) | 104 | 7 | (122) | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Non-cash adjustments to operating expenses | $ | (125) | $ | (1,076) | $ | (424) | $ | (1,448) | $ | 315 | ||||||||||||||||||||||
| Outpatient Medical | 104,711 | 104,097 | 103,568 | 111,118 | 109,238 | |||||||||||||||||||||||||||
| Lab | 64,027 | 59,603 | 61,586 | 66,789 | 66,430 | |||||||||||||||||||||||||||
| Life Plan | 109,917 | 110,260 | 112,292 | 113,910 | 113,884 | |||||||||||||||||||||||||||
| Other | 16,136 | 16,313 | 16,544 | 16,862 | 16,629 | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Portfolio Cash Operating Expenses | $ | 294,791 | $ | 290,273 | $ | 293,990 | $ | 308,679 | $ | 306,181 | ||||||||||||||||||||||
![]() |
14 |
||||
| Reconciliations | ||
| Operating Expenses | ||
| Three Months Ended | ||||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Outpatient Medical | $ | (7,405) | $ | (8,352) | $ | (8,407) | $ | (8,964) | $ | (7,828) | ||||||||||||||||||||||
| Lab | (15,267) | (13,216) | (14,344) | (15,717) | (15,798) | |||||||||||||||||||||||||||
| Life Plan | (141) | (18) | (55) | (41) | (366) | |||||||||||||||||||||||||||
| Other | (16,136) | (16,313) | (16,544) | (16,862) | (16,629) | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Merger-Combined non-SS Cash Operating Expenses | $ | (38,949) | $ | (37,899) | $ | (39,350) | $ | (41,584) | $ | (40,621) | ||||||||||||||||||||||
| Outpatient Medical | 97,306 | 95,745 | 95,161 | 102,154 | 101,410 | |||||||||||||||||||||||||||
| Lab | 48,760 | 46,387 | 47,242 | 51,072 | 50,632 | |||||||||||||||||||||||||||
| Life Plan | 109,776 | 110,242 | 112,237 | 113,869 | 113,518 | |||||||||||||||||||||||||||
| Other | — | — | — | — | — | |||||||||||||||||||||||||||
| Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
| Merger-Combined SS Cash Operating Expenses | $ | 255,842 | $ | 252,374 | $ | 254,640 | $ | 267,095 | $ | 265,560 | ||||||||||||||||||||||
![]() |
15 |
||||
| Reconciliations | ||
| Revenue | Operating Expenses | |||||||
| Year Ended December 31, 2025 |
Year Ended December 31, 2025 |
||||||||||||||||
| Outpatient Medical | $ | 1,296,677 | Outpatient Medical | $ | 436,050 | ||||||||||||
| Lab | 860,066 | Lab | 245,195 | ||||||||||||||
| Life Plan | 603,989 | Life Plan | 447,854 | ||||||||||||||
| Other | 56,165 | Other | — | ||||||||||||||
| Corporate Non-segment | 5,615 | Corporate Non-segment | — | ||||||||||||||
| Total revenues | $ | 2,822,512 | Operating expenses | $ | 1,129,099 | ||||||||||||
| Outpatient Medical | — | Outpatient Medical | 11,332 | ||||||||||||||
| Lab | — | Lab | 8,279 | ||||||||||||||
| Life Plan | — | Life Plan | — | ||||||||||||||
| Other | (56,165) | Other | 66,371 | ||||||||||||||
| Corporate Non-segment | (5,615) | Corporate Non-segment | — | ||||||||||||||
| Less: Interest income and other | $ | (61,780) | Healthpeak's share of unconsolidated joint venture operating expenses | $ | 85,982 | ||||||||||||
| Outpatient Medical | 29,326 | Outpatient Medical | (13,265) | ||||||||||||||
| Lab | 25,303 | Lab | (99) | ||||||||||||||
| Life Plan | — | Life Plan | — | ||||||||||||||
| Other | 89,439 | Other | — | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Healthpeak's share of unconsolidated joint venture real estate revenues | $ | 144,068 | Noncontrolling interests' share of consolidated joint venture operating expenses | $ | (13,364) | ||||||||||||
| Outpatient Medical | (41,082) | Outpatient Medical | (6,098) | ||||||||||||||
| Lab | (137) | Lab | 1,033 | ||||||||||||||
| Life Plan | — | Life Plan | 2,492 | ||||||||||||||
| Other | — | Other | (23) | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Noncontrolling interests' share of consolidated joint venture real estate revenues | $ | (41,219) | Non-cash adjustments to operating expenses | $ | (2,596) | ||||||||||||
| Outpatient Medical | (50,141) | Outpatient Medical | 428,019 | ||||||||||||||
| Lab | (63,457) | Lab | 254,408 | ||||||||||||||
| Life Plan | — | Life Plan | 450,346 | ||||||||||||||
| Other | 6 | Other | 66,348 | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Non-cash adjustments to real estate revenues | $ | (113,592) | Portfolio Cash Operating Expenses | $ | 1,199,121 | ||||||||||||
![]() |
16 |
||||
| Reconciliations | ||
| Revenue | Operating Expenses | |||||||
| Year Ended December 31, 2025 |
Year Ended December 31, 2025 |
||||||||||||||||
| Outpatient Medical | $ | 1,234,780 | Outpatient Medical | $ | (34,794) | ||||||||||||
| Lab | 821,775 | Lab | (61,977) | ||||||||||||||
| Life Plan | 603,989 | Life Plan | (480) | ||||||||||||||
| Other | 89,445 | Other | (66,348) | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Portfolio Cash Real Estate Revenues | $ | 2,749,989 | Merger-Combined non-SS Cash Operating Expenses | $ | (163,599) | ||||||||||||
| Outpatient Medical | (84,813) | Outpatient Medical | 393,225 | ||||||||||||||
| Lab | (157,579) | Lab | 192,431 | ||||||||||||||
| Life Plan | — | Life Plan | 449,866 | ||||||||||||||
| Other | (89,445) | Other | — | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Merger-Combined non-SS Cash Real Estate Revenues | $ | (331,837) | Merger-Combined SS Cash Operating Expenses | $ | 1,035,522 | ||||||||||||
| Outpatient Medical | 1,149,967 | ||||||||||||||||
| Lab | 664,196 | ||||||||||||||||
| Life Plan | 603,989 | ||||||||||||||||
| Other | — | ||||||||||||||||
| Corporate Non-segment | — | ||||||||||||||||
| Merger-Combined SS Cash Real Estate Revenues | $ | 2,418,152 | |||||||||||||||
![]() |
17 |
||||
| Reconciliations | ||
| Revenue | Operating Expenses | |||||||
| Year Ended December 31, 2024 |
Year Ended December 31, 2024 |
||||||||||||||||
| Outpatient Medical | $ | 1,205,744 | Outpatient Medical | $ | 405,993 | ||||||||||||
| Lab | 881,452 | Lab | 239,620 | ||||||||||||||
| Life Plan | 568,475 | Life Plan | 429,248 | ||||||||||||||
| Other | 40,262 | Other | — | ||||||||||||||
| Corporate Non-segment | 4,516 | Corporate Non-segment | — | ||||||||||||||
| Total revenues | $ | 2,700,449 | Operating expenses | $ | 1,074,861 | ||||||||||||
| Outpatient Medical | — | Outpatient Medical | 9,034 | ||||||||||||||
| Lab | — | Lab | 6,366 | ||||||||||||||
| Life Plan | — | Life Plan | — | ||||||||||||||
| Other | (40,262) | Other | 64,339 | ||||||||||||||
| Corporate Non-segment | (4,516) | Corporate Non-segment | — | ||||||||||||||
| Less: Interest income and other | $ | (44,778) | Healthpeak's share of unconsolidated joint venture operating expenses | $ | 79,739 | ||||||||||||
| Outpatient Medical | 24,041 | Outpatient Medical | (10,582) | ||||||||||||||
| Lab | 19,733 | Lab | (52) | ||||||||||||||
| Life Plan | — | Life Plan | — | ||||||||||||||
| Other | 86,642 | Other | — | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Healthpeak's share of unconsolidated joint venture real estate revenues | $ | 130,416 | Noncontrolling interests' share of consolidated joint venture operating expenses | $ | (10,634) | ||||||||||||
| Outpatient Medical | (37,643) | Outpatient Medical | (6,087) | ||||||||||||||
| Lab | (196) | Lab | 1,137 | ||||||||||||||
| Life Plan | — | Life Plan | 3,123 | ||||||||||||||
| Other | — | Other | (338) | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Noncontrolling interests' share of consolidated joint venture real estate revenues | $ | (37,839) | Non-cash adjustments to operating expenses | $ | (2,165) | ||||||||||||
| Outpatient Medical | (45,054) | Outpatient Medical | 398,358 | ||||||||||||||
| Lab | (63,312) | Lab | 247,071 | ||||||||||||||
| Life Plan | — | Life Plan | 432,371 | ||||||||||||||
| Other | (239) | Other | 64,001 | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Non-cash adjustments to real estate revenues | $ | (108,605) | Portfolio Cash Operating Expenses | $ | 1,141,801 | ||||||||||||
![]() |
18 |
||||
| Reconciliations | ||
| Revenue | Operating Expenses | |||||||
| Year Ended December 31, 2024 |
Year Ended December 31, 2024 |
||||||||||||||||
| Outpatient Medical | $ | 1,147,088 | Outpatient Medical | $ | 29,131 | ||||||||||||
| Lab | 837,677 | Lab | — | ||||||||||||||
| Life Plan | 568,475 | Life Plan | — | ||||||||||||||
| Other | 86,403 | Other | — | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-Segment | — | ||||||||||||||
| Portfolio Cash Real Estate Revenues | $ | 2,639,643 | Pre-Merger legacy Physicians Realty Trust Cash Operating Expenses | $ | 29,131 | ||||||||||||
| Outpatient Medical | 90,529 | Outpatient Medical | (48,465) | ||||||||||||||
| Lab | — | Lab | (58,453) | ||||||||||||||
| Life Plan | — | Life Plan | (814) | ||||||||||||||
| Other | — | Other | (64,001) | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Cash Real Estate Revenue | $ | 90,529 | Merger-Combined non-SS Cash Operating Expenses | $ | (171,733) | ||||||||||||
| Outpatient Medical | (130,482) | Outpatient Medical | 379,024 | ||||||||||||||
| Lab | (184,241) | Lab | 188,618 | ||||||||||||||
| Life Plan | — | Life Plan | 431,557 | ||||||||||||||
| Other | (86,403) | Other | — | ||||||||||||||
| Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
| Merger-Combined non-SS Cash Real Estate Revenues | $ | (401,126) | Merger-Combined SS Cash Operating Expenses | $ | 999,199 | ||||||||||||
| Outpatient Medical | 1,107,135 | ||||||||||||||||
| Lab | 653,436 | ||||||||||||||||
| Life Plan | 568,475 | ||||||||||||||||
| Other | — | ||||||||||||||||
| Corporate Non-segment | — | ||||||||||||||||
| Merger-Combined SS Cash Real Estate Revenues | $ | 2,329,046 | |||||||||||||||
![]() |
19 |
||||
| Reconciliations | ||
| Segment Portfolio NOI and Adjusted NOI, Portfolio Income, and SS | ||
| Total Portfolio | Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | 10,672 | $ | 50,064 | $ | 39,019 | $ | (109,848) | $ | 121,792 | ||||||||||||||||||||||
| Interest income and other | (16,894) | (15,821) | (15,806) | (15,529) | (14,624) | |||||||||||||||||||||||||||
| Interest expense | 70,508 | 72,693 | 75,063 | 76,784 | 80,638 | |||||||||||||||||||||||||||
| Depreciation and amortization | 274,469 | 268,546 | 265,916 | 262,317 | 262,086 | |||||||||||||||||||||||||||
| General and administrative | 23,929 | 26,118 | 20,764 | 19,907 | 23,627 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 10,572 | 5,534 | 10,215 | 2,420 | 7,351 | |||||||||||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | 11,632 | (3,562) | 3,499 | (54) | (776) | |||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | 8,929 | — | (1,636) | (11,500) | (56,352) | |||||||||||||||||||||||||||
| Other (income) expense, net | 24,157 | 6,126 | 4,692 | (1,160) | (10,137) | |||||||||||||||||||||||||||
| Income tax (benefit) expense | (14,014) | 2,080 | 2,382 | (1,206) | 6,027 | |||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 108 | 2,147 | (1,747) | 176,291 | (2,707) | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 13,926 | 11,534 | 15,968 | 14,684 | 15,900 | |||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (7,000) | (7,195) | (7,219) | (6,569) | (6,872) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(25,700) | (26,914) | (24,181) | (25,900) | (34,001) | |||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 385,294 | $ | 391,350 | $ | 386,929 | $ | 380,637 | $ | 391,952 | ||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (45,117) | (41,615) | (40,376) | (39,179) | (38,610) | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 340,177 | $ | 349,735 | $ | 346,553 | $ | 341,458 | $ | 353,342 | ||||||||||||||||||||||
Outpatient Medical |
Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | 32,066 | $ | 51,216 | $ | 54,395 | $ | 64,948 | $ | 116,100 | ||||||||||||||||||||||
| Interest expense | 3,686 | 3,573 | 3,476 | 3,571 | 3,457 | |||||||||||||||||||||||||||
| Depreciation and amortization | 162,592 | 157,131 | 156,714 | 154,485 | 152,814 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 1,137 | 248 | 12 | 298 | 377 | |||||||||||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | 13,118 | — | — | — | — | |||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (5,832) | — | (2,932) | (11,500) | (56,352) | |||||||||||||||||||||||||||
| Other (income) expense, net | 1,122 | (49) | 652 | (1,350) | (1,390) | |||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 2,870 | 3,204 | 2,834 | 2,449 | 2,246 | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 4,679 | 4,265 | 4,488 | 4,440 | 4,801 | |||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (7,000) | (7,195) | (7,219) | (6,569) | (6,834) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(11,390) | (12,082) | (10,813) | (10,358) | (10,790) | |||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 197,048 | $ | 200,311 | $ | 201,607 | $ | 200,414 | $ | 204,429 | ||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (13,179) | (11,970) | (11,830) | (11,710) | (13,022) | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 183,869 | $ | 188,341 | $ | 189,777 | $ | 188,704 | $ | 191,407 | ||||||||||||||||||||||
![]() |
20 |
||||
| Reconciliations | ||
| Segment Portfolio NOI and Adjusted NOI, Portfolio Income, and SS | ||
| Lab | Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | 83,305 | $ | 80,403 | $ | 74,328 | $ | (104,187) | $ | 80,964 | ||||||||||||||||||||||
| Depreciation and amortization | 77,127 | 78,616 | 78,010 | 76,946 | 77,792 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 12 | 337 | 295 | 232 | 206 | |||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (298) | — | — | — | — | |||||||||||||||||||||||||||
| Other (income) expense, net | (2,496) | (13) | (20) | (138) | (26) | |||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | (1,866) | 592 | (2,809) | 176,120 | (2,777) | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 3,626 | 1,134 | 5,460 | 4,605 | 5,825 | |||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | — | — | — | — | (38) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(12,825) | (14,836) | (12,488) | (15,520) | (21,646) | |||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 146,585 | $ | 146,233 | $ | 142,776 | $ | 138,058 | $ | 140,300 | ||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (26,464) | (23,524) | (22,618) | (21,893) | (20,596) | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 120,121 | $ | 122,709 | $ | 120,158 | $ | 116,165 | $ | 119,704 | ||||||||||||||||||||||
| Life Plan | Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | (25,978) | $ | (1,679) | $ | 303 | $ | 4,439 | $ | 18,491 | ||||||||||||||||||||||
| Interest expense | 978 | 948 | 949 | 951 | 950 | |||||||||||||||||||||||||||
| Depreciation and amortization | 34,750 | 32,799 | 31,192 | 30,886 | 31,480 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 11 | 14 | 215 | — | (229) | |||||||||||||||||||||||||||
| Other (income) expense, net | 27,764 | 6,585 | 4,747 | 272 | (7,178) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(1,479) | — | (843) | — | (1,649) | |||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 36,046 | $ | 38,667 | $ | 36,563 | $ | 36,548 | $ | 41,865 | ||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | 141 | 18 | 55 | 41 | 366 | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 36,187 | $ | 38,685 | $ | 36,618 | $ | 36,589 | $ | 42,231 | ||||||||||||||||||||||
| Other | Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | 2,522 | $ | 19,004 | $ | 10,907 | $ | 15,983 | $ | 15,663 | ||||||||||||||||||||||
| Interest income and other | (15,199) | (14,332) | (14,288) | (14,092) | (13,453) | |||||||||||||||||||||||||||
| Transaction and merger-related costs | — | 433 | 393 | (5) | 47 | |||||||||||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | (1,486) | (3,562) | 3,499 | (54) | (776) | |||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | 15,059 | — | 1,296 | — | — | |||||||||||||||||||||||||||
| Other (income) expense, net | — | 106 | (35) | 446 | 695 | |||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | (896) | (1,649) | (1,772) | (2,278) | (2,176) | |||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 5,621 | 6,135 | 6,020 | 5,639 | 5,274 | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(6) | 4 | (37) | (22) | 84 | |||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 5,615 | $ | 6,139 | $ | 5,983 | $ | 5,617 | $ | 5,358 | ||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (5,615) | (6,139) | (5,983) | (5,617) | (5,358) | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
![]() |
21 |
||||
| Reconciliations | ||
| Segment Portfolio NOI and Adjusted NOI, Portfolio Income, and SS | ||
Corporate Non-Segment |
Three Months Ended | |||||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||||||
| Net income (loss) | $ | (81,243) | $ | (98,880) | $ | (100,914) | $ | (91,031) | $ | (109,426) | ||||||||||||||||||||||
| Interest income and other | (1,695) | (1,489) | (1,518) | (1,437) | (1,171) | |||||||||||||||||||||||||||
| Interest expense | 65,844 | 68,172 | 70,638 | 72,262 | 76,231 | |||||||||||||||||||||||||||
| General and administrative | 23,929 | 26,118 | 20,764 | 19,907 | 23,627 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 9,412 | 4,502 | 9,300 | 1,895 | 6,950 | |||||||||||||||||||||||||||
| Other (income) expense, net | (2,233) | (503) | (652) | (390) | (2,238) | |||||||||||||||||||||||||||
| Income tax (benefit) expense | (14,014) | 2,080 | 2,382 | (1,206) | 6,027 | |||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
![]() |
22 |
||||
| Reconciliations | ||
| Segment Portfolio NOI and Adjusted NOI, Portfolio Income, and SS | ||
| Outpatient Medical |
Lab | Life Plan | Other Non- reportable |
Corporate Non-segment |
Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 286,659 | $ | 131,508 | $ | 21,554 | $ | 61,557 | $ | (400,251) | $ | 101,027 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (56,165) | (5,615) | (61,780) | ||||||||||||||||||||||||||||||||
| Interest expense | 14,077 | — | 3,798 | — | 287,303 | 305,178 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 621,144 | 311,364 | 126,357 | — | — | 1,058,865 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 90,416 | 90,416 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 935 | 1,070 | — | 868 | 22,647 | 25,520 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | — | — | — | (893) | — | (893) | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (70,784) | — | — | 1,296 | — | (69,488) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (2,137) | (197) | 4,426 | 1,212 | (3,783) | (479) | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 9,283 | 9,283 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 10,733 | 171,126 | — | (7,875) | — | 173,984 | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 17,994 | 17,024 | — | 23,068 | — | 58,086 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (27,817) | (38) | — | — | — | (27,855) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) |
(44,043) | (64,490) | (2,492) | 29 | — | (110,996) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 806,761 | $ | 567,367 | $ | 153,643 | $ | 23,097 | $ | — | $ | 1,550,868 | ||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (50,019) | (95,602) | 480 | (23,097) | — | (168,238) | ||||||||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 756,742 | $ | 471,765 | $ | 154,123 | $ | — | $ | — | $ | 1,382,630 | ||||||||||||||||||||||||||
![]() |
23 |
||||
| Reconciliations | ||
| Segment Portfolio NOI and Adjusted NOI, Portfolio Income, and SS | ||
| Outpatient Medical |
Lab | Life Plan | Other Non- reportable |
Corporate Non-segment |
Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 285,296 | $ | 477,173 | $ | (31,137) | $ | 17,275 | $ | (481,304) | $ | 267,303 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (40,262) | (4,516) | (44,778) | ||||||||||||||||||||||||||||||||
| Interest expense | 15,155 | — | 3,942 | — | 261,333 | 280,430 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 610,412 | 309,607 | 137,186 | — | — | 1,057,205 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 97,162 | 97,162 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 2,180 | 503 | 60 | — | 129,942 | 132,685 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves (recoveries), net | 13,118 | — | — | 9,860 | — | 22,978 | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (138,243) | (55,511) | — | 15,059 | — | (178,695) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (254) | (81,262) | 29,176 | (38) | (6,967) | (59,345) | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 4,350 | 4,350 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 12,087 | (8,678) | — | (1,894) | — | 1,515 | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 15,007 | 13,367 | — | 22,303 | — | 50,677 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (27,061) | (144) | — | — | — | (27,205) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) |
(38,967) | (64,449) | (3,123) | 99 | — | (106,440) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 748,730 | $ | 590,606 | $ | 136,104 | $ | 22,402 | $ | — | $ | 1,497,842 | ||||||||||||||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 61,398 | — | — | — | — | 61,398 | ||||||||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (82,017) | (125,788) | 814 | (22,402) | — | (229,393) | ||||||||||||||||||||||||||||||||
| Merger-Combined SS Adjusted NOI | $ | 728,111 | $ | 464,818 | $ | 136,918 | $ | — | $ | — | $ | 1,329,847 | ||||||||||||||||||||||||||
![]() |
24 |
||||
| Reconciliations | ||
| Property Count Reconciliations | ||
| As of December 31, 2025 | |||||||||||||||||||||||||||||
| Property Count Reconciliation | |||||||||||||||||||||||||||||
| Outpatient Medical |
Lab | Life Plan | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Total Property Count | 530 | 139 | 15 | 19 | 703 | ||||||||||||||||||||||||
| Acquisitions | 2 | 7 | — | — | 9 | ||||||||||||||||||||||||
| Assets sold | (23) | — | — | — | (23) | ||||||||||||||||||||||||
| Current Quarter Total Property Count | 509 | 146 | 15 | 19 | 689 | ||||||||||||||||||||||||
| Recent acquisitions | (8) | (7) | — | — | (15) | ||||||||||||||||||||||||
| Assets in Development | (5) | (2) | — | — | (7) | ||||||||||||||||||||||||
| Recently completed Developments | (3) | (2) | — | — | (5) | ||||||||||||||||||||||||
| Assets in Redevelopment | (4) | (20) | — | — | (24) | ||||||||||||||||||||||||
| Recently completed Redevelopments | (1) | (6) | — | — | (7) | ||||||||||||||||||||||||
| Assets held for sale | (2) | (6) | — | — | (8) | ||||||||||||||||||||||||
| Other exclusions | — | — | — | (19) | (19) | ||||||||||||||||||||||||
| Significant tenant relocation | — | (1) | — | — | (1) | ||||||||||||||||||||||||
| Three-Month SS Property Count | 486 | 102 | 15 | — | 603 | ||||||||||||||||||||||||
| Prior Development/Redevelopment | (1) | (3) | — | — | (4) | ||||||||||||||||||||||||
| Twelve-Month SS Property Count | 485 | 99 | 15 | — | 599 | ||||||||||||||||||||||||
| Sequential SS | |||||||||||||||||||||||||||||
| Outpatient Medical |
Lab | Life Plan | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Three-Month SS Property Count | 514 | 102 | 15 | — | 631 | ||||||||||||||||||||||||
| Assets in Redevelopment | (4) | (1) | — | — | (5) | ||||||||||||||||||||||||
| Prior Development/Redevelopment | — | 1 | — | — | 1 | ||||||||||||||||||||||||
| Assets held for sale | (2) | — | — | — | (2) | ||||||||||||||||||||||||
| Assets sold | (22) | — | — | — | (22) | ||||||||||||||||||||||||
| Current Quarter Three-Month SS Property Count | 486 | 102 | 15 | — | 603 | ||||||||||||||||||||||||
![]() |
25 |
||||
| Reconciliations | ||
| Common Stock and Equivalents | ||
| Weighted Average Shares | Weighted Average Shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Three Months Ended
December 31, 2025
|
Twelve Months Ended
December 31, 2025
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares Outstanding
December 31, 2025
|
Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | |||||||||||||||||||||||||||||||||||||||||||||
| Common stock | 695,037 | 694,976 | 694,976 | 694,976 | 694,976 | 696,026 | 696,026 | 696,026 | 696,026 | ||||||||||||||||||||||||||||||||||||||||||||
Common stock equivalent securities(1): |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units | 559 | 9 | 9 | 9 | 9 | 18 | 18 | 18 | 18 | ||||||||||||||||||||||||||||||||||||||||||||
| OP units | 4,323 | — | 1,044 | 1,044 | 1,044 | — | 1,044 | 1,044 | 1,044 | ||||||||||||||||||||||||||||||||||||||||||||
| Convertible partnership units | 13,365 | — | 13,383 | 13,383 | 13,383 | — | 13,421 | 13,421 | 13,421 | ||||||||||||||||||||||||||||||||||||||||||||
| Total common stock and equivalents | 713,284 | 694,985 | 709,412 | 709,412 | 709,412 | 696,044 | 710,509 | 710,509 | 710,509 | ||||||||||||||||||||||||||||||||||||||||||||
![]() |
26 |
||||
| Reconciliations | ||
| Net Income to Adjusted EBITDAre | ||
| Three Months Ended December 31, 2025 |
|||||
| Net income (loss) | $ | 121,792 | |||
| Interest expense | 80,638 | ||||
| Income tax expense (benefit) | 6,027 | ||||
| Depreciation and amortization | 262,086 | ||||
| Other depreciation and amortization | 656 | ||||
| Loss (gain) on sales of real estate | (56,352) | ||||
| Share of unconsolidated JV: | |||||
| Interest expense | 3,506 | ||||
| Income tax expense (benefit) | (139) | ||||
| Depreciation and amortization | 12,806 | ||||
| EBITDAre | $ | 431,020 | |||
| Transaction, merger, and restructuring-related costs | 7,351 | ||||
| Other impairments (recoveries) and other losses (gains) | (776) | ||||
| Casualty-related charges (recoveries) | (9,204) | ||||
| Life plan community entrance fees | 17,355 | ||||
| Stock-based compensation amortization expense | 4,000 | ||||
Impact of transactions closed during the period(1) |
3,815 | ||||
| Adjusted EBITDAre | $ | 453,561 | |||
Impact of transactions closed during the period(1) |
(3,815) | ||||
Fixed Charge Coverage Adjusted EBITDAre(2) |
$ | 449,746 | |||
| Adjusted Fixed Charge Coverage | ||
| Three Months Ended December 31, 2025 |
|||||
| Interest expense, including unconsolidated JV interest expense at share | $ | 84,144 | |||
| Capitalized interest, including unconsolidated JV capitalized interest at share | 19,973 | ||||
| Fixed Charges | $ | 104,117 | |||
Adjusted Fixed Charge Coverage(2) |
4.3x | ||||
![]() |
27 |
||||
| Reconciliations | ||
| Enterprise Debt and Net Debt | ||
| December 31, 2025 | |||||
| Bank line of credit and commercial paper | $ | 1,078,850 | |||
| Term loans | 1,647,113 | ||||
| Senior unsecured notes | 6,772,722 | ||||
| Mortgage debt | 349,209 | ||||
| Consolidated Debt | $ | 9,847,894 | |||
| Share of unconsolidated JV mortgage debt | 209,768 | ||||
| Enterprise Debt | $ | 10,057,662 | |||
| Cash and cash equivalents | (467,457) | ||||
| Share of unconsolidated JV cash and cash equivalents | (23,331) | ||||
| Restricted cash | (70,245) | ||||
| Share of unconsolidated JV restricted cash | (1,657) | ||||
| Net Debt | $ | 9,494,972 | |||
| Financial Leverage | ||
| December 31, 2025 | |||||
| Enterprise Debt | $ | 10,057,662 | |||
| Enterprise Gross Assets | 26,149,968 | ||||
| Financial Leverage | 38.5% | ||||
| Secured Debt Ratio | ||
| December 31, 2025 | |||||
| Mortgage debt | $ | 349,209 | |||
| Share of unconsolidated JV mortgage debt | 209,768 | ||||
| Enterprise Secured Debt | $ | 558,977 | |||
| Enterprise Gross Assets | $ | 26,149,968 | |||
| Secured Debt Ratio | 2.1% | ||||
| Net Debt to Adjusted EBITDAre | ||
| Three Months Ended December 31, 2025 |
|||||
| Net Debt | $ | 9,494,972 | |||
Annualized Adjusted EBITDAre(1) |
1,814,244 | ||||
| Net Debt to Adjusted EBITDAre | 5.2x | ||||
![]() |
28 |
||||
| Reconciliations | ||
| Healthpeak's Share of Unconsolidated Joint Venture NOI | ||
| Total Portfolio | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | (108) | $ | (2,147) | $ | 1,747 | $ | (176,291) | $ | 2,707 | |||||||||||||||||||
| Depreciation and amortization | 12,441 | 12,200 | 12,530 | 12,574 | 12,806 | ||||||||||||||||||||||||
| General and administrative | 348 | 350 | 352 | 340 | 425 | ||||||||||||||||||||||||
| Other (income) expense, net | 1,039 | 861 | 1,089 | 66 | 92 | ||||||||||||||||||||||||
| Income tax (benefit) expense | 206 | 270 | 250 | 155 | (130) | ||||||||||||||||||||||||
Impairments (recoveries) of real estate, net |
— | — | — | 177,840 | — | ||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 13,926 | $ | 11,534 | $ | 15,968 | $ | 14,684 | $ | 15,900 | |||||||||||||||||||
| Outpatient Medical | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | (2,870) | $ | (3,204) | $ | (2,834) | $ | (2,449) | $ | (2,246) | |||||||||||||||||||
| Depreciation and amortization | 4,388 | 4,128 | 4,039 | 3,859 | 3,813 | ||||||||||||||||||||||||
| General and administrative | 95 | 159 | 97 | 22 | 166 | ||||||||||||||||||||||||
| Other (income) expense, net | 3,074 | 3,193 | 3,178 | 2,999 | 3,059 | ||||||||||||||||||||||||
| Income tax (benefit) expense | (8) | (11) | 8 | 9 | 9 | ||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 4,679 | $ | 4,265 | $ | 4,488 | $ | 4,440 | $ | 4,801 | |||||||||||||||||||
| Lab | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | 1,865 | $ | (592) | $ | 2,809 | $ | (176,120) | $ | 2,777 | |||||||||||||||||||
| Depreciation and amortization | 3,380 | 3,346 | 3,714 | 3,943 | 4,172 | ||||||||||||||||||||||||
| General and administrative | 258 | 151 | 249 | 272 | 241 | ||||||||||||||||||||||||
| Other (income) expense, net | (1,877) | (1,771) | (1,312) | (1,330) | (1,365) | ||||||||||||||||||||||||
Impairments (recoveries) of real estate, net |
— | — | — | 177,840 | — | ||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 3,626 | $ | 1,134 | $ | 5,460 | $ | 4,605 | $ | 5,825 | |||||||||||||||||||
| Other | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | 897 | $ | 1,649 | $ | 1,772 | $ | 2,278 | $ | 2,176 | |||||||||||||||||||
| Depreciation and amortization | 4,673 | 4,726 | 4,777 | 4,772 | 4,821 | ||||||||||||||||||||||||
| General and administrative | (5) | 40 | 6 | 46 | 18 | ||||||||||||||||||||||||
| Other (income) expense, net | (158) | (561) | (777) | (1,603) | (1,602) | ||||||||||||||||||||||||
| Income tax (benefit) expense | 214 | 281 | 242 | 146 | (139) | ||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 5,621 | $ | 6,135 | $ | 6,020 | $ | 5,639 | $ | 5,274 | |||||||||||||||||||
![]() |
29 |
||||
| Reconciliations | ||
| Healthpeak's Share of Unconsolidated Joint Venture NOI | ||
| Outpatient Medical |
Lab | Other | Total | |||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | (10,733) | $ | (171,126) | $ | 7,875 | $ | (173,984) | ||||||||||||||||||
| Depreciation and amortization | 15,839 | 15,175 | 19,096 | 50,110 | ||||||||||||||||||||||
| General and administrative | 444 | 913 | 110 | 1,467 | ||||||||||||||||||||||
| Other (income) expense, net | 12,429 | (5,778) | (4,543) | 2,108 | ||||||||||||||||||||||
| Income tax (benefit) expense | 15 | — | 530 | 545 | ||||||||||||||||||||||
Impairments (recoveries) of real estate, net |
— | 177,840 | — | 177,840 | ||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 17,994 | $ | 17,024 | $ | 23,068 | $ | 58,086 | ||||||||||||||||||
| Outpatient Medical |
Lab | Other | Total | |||||||||||||||||||||||
| Equity income (loss) from unconsolidated joint ventures | $ | (12,087) | $ | 8,677 | $ | 1,895 | $ | (1,515) | ||||||||||||||||||
| Depreciation and amortization | 14,526 | 11,840 | 18,595 | 44,961 | ||||||||||||||||||||||
| General and administrative | 363 | 664 | 90 | 1,117 | ||||||||||||||||||||||
| Other (income) expense, net | 12,220 | (7,814) | 1,181 | 5,587 | ||||||||||||||||||||||
| Income tax (benefit) expense | (15) | — | 542 | 527 | ||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | $ | 15,007 | $ | 13,367 | $ | 22,303 | $ | 50,677 | ||||||||||||||||||
![]() |
30 |
||||
| Reconciliations | ||
| Noncontrolling Interests' Share of Consolidated Joint Venture NOI | ||
| Total Portfolio | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 6,125 | $ | 7,236 | $ | 7,346 | $ | 7,274 | $ | 7,824 | |||||||||||||||||||
| Depreciation and amortization | 4,520 | 4,353 | 4,350 | 3,721 | 3,731 | ||||||||||||||||||||||||
| Other (income) expense, net | 923 | 422 | 264 | 340 | 121 | ||||||||||||||||||||||||
| Dividends attributable to noncontrolling interest | (4,568) | (4,816) | (4,741) | (4,766) | (4,804) | ||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | 7,000 | $ | 7,195 | $ | 7,219 | $ | 6,569 | $ | 6,872 | |||||||||||||||||||
| Outpatient Medical | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 4,890 | $ | 5,792 | $ | 5,894 | $ | 5,848 | $ | 6,322 | |||||||||||||||||||
| Depreciation and amortization | 4,520 | 4,353 | 4,350 | 3,721 | 3,731 | ||||||||||||||||||||||||
| Other (income) expense, net | 923 | 422 | 324 | 340 | 121 | ||||||||||||||||||||||||
| Dividends attributable to noncontrolling interest | (3,333) | (3,372) | (3,349) | (3,340) | (3,340) | ||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | 7,000 | $ | 7,195 | $ | 7,219 | $ | 6,569 | $ | 6,834 | |||||||||||||||||||
| Lab | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 913 | $ | 898 | $ | 928 | $ | 898 | $ | 966 | |||||||||||||||||||
| Dividends attributable to noncontrolling interest | (913) | (898) | (928) | (898) | (928) | ||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | — | $ | — | $ | — | $ | — | $ | 38 | |||||||||||||||||||
| Corporate Non-segment | Three Months Ended | ||||||||||||||||||||||||||||
| December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
|||||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 322 | $ | 546 | $ | 524 | $ | 528 | $ | 536 | |||||||||||||||||||
| Dividends attributable to noncontrolling interest | (322) | (546) | (524) | (528) | (536) | ||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||
![]() |
31 |
||||
| Reconciliations | ||
| Noncontrolling Interests' Share of Consolidated Joint Venture NOI | ||
| Outpatient Medical |
Lab | Corporate Non-segment |
Total | |||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 23,856 | $ | 3,690 | $ | 2,134 | $ | 29,680 | ||||||||||||||||||
| Depreciation and amortization | 16,155 | — | — | 16,155 | ||||||||||||||||||||||
| Other (income) expense, net | 1,207 | — | — | 1,207 | ||||||||||||||||||||||
| Dividends attributable to noncontrolling interest | (13,401) | (3,652) | (2,134) | (19,187) | ||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | 27,817 | $ | 38 | $ | — | $ | 27,855 | ||||||||||||||||||
| Outpatient Medical |
Lab | Corporate Non-segment |
Total | |||||||||||||||||||||||
| Income (loss) from continuing operations attributable to noncontrolling interest | $ | 19,215 | $ | 3,789 | $ | 1,157 | $ | 24,161 | ||||||||||||||||||
| Depreciation and amortization | 17,939 | 61 | — | 18,000 | ||||||||||||||||||||||
| Other (income) expense, net | 1,423 | (84) | — | 1,339 | ||||||||||||||||||||||
| Dividends attributable to noncontrolling interest | (11,516) | (3,622) | (1,157) | (16,295) | ||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | $ | 27,061 | $ | 144 | $ | — | $ | 27,205 | ||||||||||||||||||
![]() |
32 |
||||
| Reconciliations | ||
REVPOR Life Plan(1) | ||
| Three Months Ended | |||||||||||||||||||||||||||||
| REVPOR Life Plan | December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||
Portfolio Cash Real Estate Revenues(2) |
$ | 145,963 | $ | 148,927 | $ | 148,855 | $ | 150,458 | $ | 155,749 | |||||||||||||||||||
| REVPOR Life Plan revenues | $ | 145,963 | $ | 148,927 | $ | 148,855 | $ | 150,458 | $ | 155,749 | |||||||||||||||||||
| Average occupied units/month | 6,060 | 6,085 | 6,074 | 6,121 | 6,179 | ||||||||||||||||||||||||
REVPOR Life Plan per month(3) |
$ | 8,028 | $ | 8,158 | $ | 8,169 | $ | 8,193 | $ | 8,403 | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| REVPOR Life Plan excluding NREF Amortization | December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||
| REVPOR Life Plan revenues | $ | 145,963 | $ | 148,927 | $ | 148,855 | $ | 150,458 | $ | 155,749 | |||||||||||||||||||
| NREF Amortization | (23,394) | (24,006) | (23,652) | (24,155) | (27,099) | ||||||||||||||||||||||||
| REVPOR Life Plan revenues excluding NREF Amortization | $ | 122,569 | $ | 124,921 | $ | 125,203 | $ | 126,302 | $ | 128,651 | |||||||||||||||||||
| Average occupied units/month | 6,060 | 6,085 | 6,074 | 6,121 | 6,179 | ||||||||||||||||||||||||
REVPOR Life Plan excluding NREF Amortization per month(3) |
$ | 6,742 | $ | 6,843 | $ | 6,871 | $ | 6,878 | $ | 6,941 | |||||||||||||||||||
![]() |
33 |
||||
| Reconciliations | ||
REVPOR(1) | ||
| Three Months Ended | |||||||||||||||||||||||||||||
| REVPOR Other | December 31, 2024 |
March 31, 2025 |
June 30, 2025 |
September 30, 2025 |
December 31, 2025 |
||||||||||||||||||||||||
Portfolio Cash Real Estate Revenues(2) |
$ | 21,751 | $ | 22,452 | $ | 22,527 | $ | 22,479 | $ | 21,987 | |||||||||||||||||||
| REVPOR revenues | $ | 21,751 | $ | 22,452 | $ | 22,527 | $ | 22,479 | $ | 21,987 | |||||||||||||||||||
| Average occupied units/month | 1,461 | 1,450 | 1,459 | 1,476 | 1,467 | ||||||||||||||||||||||||
REVPOR per month(3) |
$ | 4,963 | $ | 5,162 | $ | 5,145 | $ | 5,078 | $ | 4,996 | |||||||||||||||||||
![]() |
34 |
||||
![]() |
35 |
||||